3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Classical hematology
1
Conditions
Venous Thromboembolism
1
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Hemorrhage
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Cyclophosphamide
62
fludarabine phosphate
55
Peripheral Blood Stem Cell Transplantation
44
Tacrolimus
41
Busulfan
40
ruxolitinib
39
Mycophenolic Acid
36
Whole-Body Irradiation
32
Antilymphocyte Serum
29
Methotrexate
27
Cyclosporine
27
fludarabine
24
Melphalan
19
Filgrastim
19
Radiotherapy
15
Methylprednisolone
13
thymoglobulin
12
Etoposide
12
Cord Blood Stem Cell Transplantation
12
Azacitidine
12
Stem Cell Transplantation
11
Sirolimus
11
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
10
Decitabine
9
Specimen Handling
8
Prednisone
8
Cytarabine
8
Imatinib Mesylate
7
Granulocyte Colony-Stimulating Factor
7
Flow Cytometry
7
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Primary Myelofibrosis
×
N(4)-oleylcytosine arabinoside
×
Clear all
NCT05198960
2026-03-20
AVAJAK
University Hospital, Brest
Phase 3
Recruiting
1,308 enrolled